Phase II trial of ftorafur with mitomycin C versus ftorafur with methyl-CCNU in untreated colorectal cancer

Cancer Treat Rep. 1978 May;62(5):689-92.

Abstract

In an attempt to substitute ftorafur for burdensome 5-fluorouracil (5-FU) infusions, 52 previously untreated patients were randomized to receive ftorafur with either mitomycin C or methyl-CCNU. Ftorafur was administered monthly as a 2-hour infusion daily x 5 days. Mitomycin C and methyl-CCNU were repeated every 8 weeks. A response rate of 27% (seven responses among 26 patients) was demonstrated on the mitomycin C arm compared to a response rate of 15% (four responses among 26 patients) on the methyl-CCNU arm (P = 0.25). There was no significant difference in the median survival between treatment arms. Central nervous system toxicity occurred in greater than 30% of the patients and appeared to be the limiting factor with ftorafur administration. Alternate schedules of ftorafur should be explored since there appears to be little advantage of a daily ftorafur schedule over conventional 5-FU infusions.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adult
  • Aged
  • Clinical Trials as Topic
  • Colonic Neoplasms / drug therapy*
  • Drug Evaluation
  • Drug Therapy, Combination
  • Female
  • Fluorouracil / analogs & derivatives*
  • Humans
  • Male
  • Middle Aged
  • Mitomycins / administration & dosage
  • Mitomycins / adverse effects
  • Mitomycins / therapeutic use*
  • Nitrosourea Compounds / therapeutic use*
  • Rectal Neoplasms / drug therapy*
  • Semustine / administration & dosage
  • Semustine / adverse effects
  • Semustine / therapeutic use*
  • Tegafur / administration & dosage
  • Tegafur / adverse effects
  • Tegafur / therapeutic use*

Substances

  • Mitomycins
  • Nitrosourea Compounds
  • Semustine
  • Tegafur
  • Fluorouracil